Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pharmaust Limited ( (AU:NUZ) ) has shared an announcement.
Neurizon Therapeutics Limited has applied for quotation of 750,000 new ordinary fully paid shares on the Australian Securities Exchange, to be traded under its existing ticker NUZ. The new securities, issued on April 1, 2026, form part of a previously announced transaction, modestly expanding the company’s listed share capital and potentially affecting liquidity and ownership structure for existing shareholders.
The most recent analyst rating on (AU:NUZ) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a biotechnology company listed on the ASX under the code NUZ. The company operates in the therapeutics sector, focusing on the development of medical treatments, although this filing provides only limited operational detail beyond its status as a listed issuer.
Average Trading Volume: 595,506
Technical Sentiment Signal: Sell
Current Market Cap: A$55.94M
For a thorough assessment of NUZ stock, go to TipRanks’ Stock Analysis page.